Deepcell, a Mountain View, Calif.-based life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, closed its Series A round of financing with $20m.
The round was led by Bow Capital and joined by Andreessen Horowitz, which led its $5m seed round. Other investors include 50Y, DCVC, Stanford University, and angel investors, including Google’s head of AI Jeff Dean.
The new funding will allow the company to develop its microfluidics-based technology, continue building a cell morphology atlas of more than 400 million cells, and drive a hypothesis-free approach to cell classification and sorting.
Spun out of Stanford University in 2017 by Maddison Masaeli, co-founder and CEO, and Euan Ashley, Professor at Stanford and co-founder, Deepcell is using deep learning and big data to classify and isolate individual cells from a sample. The technology combines advances in AI, cell capture, and single-cell analysis to sort cells based on detailed visual features, delivering novel insights through an unprecedented view of cell biology. The platform maintains cell viability for downstream single-cell analysis and can be used to isolate virtually any type of cell — even those occurring at frequencies as low as one in a billion — to offer access to rare cells and atypical cell states that will help advance precision medicine research.